Artelo plans IND filing for FABP5 inhibitor ART-26.12 for neuropathic pain following FDA guidance
Sep. 8, 2023
Artelo Biosciences Inc. has completed a pre-IND meeting with the FDA regarding the manufacturing, preclinical and clinical development plan for ART-26.12.